Pharmaceutical use of substituted amides
View Patent ↗The use of substituted amides for modulating the activity of 11-hydroxysteroid dehydrogenase type 1 (11HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
1. A compound of Formula IA or a pharmaceutically acceptable salt thereof:
wherein:
R 1 is —(CH 2 ) 2 —R 6 ;
R 2 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and —C(═O)R 13 ;
the ring
Rx is hydrogen or C 1-6 alkyl, and
is substituted once with —OH;
R 6 is selected from the group consisting of cyano, aryl, hetaryl, -oxoC 1 -C 6 alkyl-S(═O) n R 13 , —C(═O)R 13 , —S(═O) n R 13 , —S(═O) n NR 18 R 19 , —N(R 18 )S(═O) n R 13 , —N(R 23 )C(═O)NR 18 R 19 , —C(═NR 15 )NR 15 , —N(R 18 )C(═O)R 13 , —N(R 18 )C(═O)—C 3 -C 6 cycloalkyl, and —N(R 18 )C(═O)—(3-6 membered hetcycloalkyl), wherein the cycloalky l, hetcycloalkyl, aryl, and hetaryl groups are substituted with 0-3 R 16 ;
R 13 is selected from the group consisting of —OH, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, C 1 -C 4 alkyloxyC 1 -C 4 alkylene, aryl, hetaryl, aryloxy, hetaryloxy, and NR 18 R 19 ;
R 15 and R 16 are independently selected from the group consisting of H, C 1 -C 4 alkyl, 3-6-membered cycloalkyl, halo, OH, cyano, —C(═O)R 13 , —S(═O ) n R 13 , —S(═O ) n NR 18 R 19 , —N(R 18 )S(═O) n R 13 , aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are substituted with 0-1 R 20 ;
R 18 and R 19 are independently selected from the group consisting of H, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, aryl, hetaryl, arylC 1 -C 4 alkylene, and hetarylC 1 -C 4 alkylene, wherein the alkyl, alkylene, aryl, and hetaryl groups are independently substituted with 0-1 R 20 ;
alternatively, R 18 and R 19 , together with the nitrogen atom to which they are attached, form a saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein this ring is substituted 0-1 times with substituents selected from the group consisting of C 1 -C 4 alkyl, aryl, hetaryl, arylC 1 -C 4 alkylene, hetarylC 1 -C 4 alkylene, hydroxy, and C 1 -C 4 alkyloxy;
R 20 is selected from the group consisting of H, OH, oxo, halo, cyano, nitro, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, NR 21 R 22 , trihalomethyl, and trihalomethyloxy;
R 21 and R 22 are independently selected from the group consisting of H, C 1 -C 4 alkyl, and arylC 1 -C 4 alkyl;
R 23 is selected from the group consisting of H and C 1 -C 6 alkyl; and
n is 2.
2. The compound of claim 1 , wherein R 2 is H.
3. The compound of claim 2 , wherein the ring
and Rx is hydrogen.
4. A compound selected from the group consisting of:
trans-1-(2-methanesulfonyl-methoxy-ethyl)-1H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
1-(2-methanesulfonyl-ethyl)-1H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
trans-1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
1-{2-[(4-hydroxy-piperidine-1-carbonyl)-amino]-ethyl}-1H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
1-{2-[(1,1-dioxo-thiomorpholine-4-carbonyl)-amino]-ethyl}-1H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
cis-1-{2-[(morpholine-4-carbonyl)-amino]-ethyl}-1H-benzo-imidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
trans-1-{2-[(morpholine-4-carbonyl)-amino]-ethyl}-lH-benzo-imidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
1-{2-[(3-hydroxy-pyrrolidine-1-carbonyl)-amino]-ethyl}-1H-benzoimidazole-5-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide;
cis-1-{2-[5-(5-hydroxy-adamantan-2-ylcarbamoyl)-benzoimidazol-1-yl]-ethylcarbamoyl}-piperidine-4-carboxylic acid; and
trans-1-{2-[5-(5-hydroxy-adamantan-2-ylcarbamoyl)-benzoimidazol-1-yl]-ethylcarbamoyl}-piperidine-4-carboxylic acid;
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
6. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or diluent.
7. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier or diluent.
8. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier or diluent.